Researchclopedia
Research
Researchers
Institutions
Topics
Submit
About
Search...
⌘
K
Command Palette
Search for a command to run...
Back to research
Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study
2026
0 citations
Journal Article
Field-Weighted Citation Impact:
0.00
Rob Burke
·
Poseida Therapeutics (United States)
Li-Jung Tai
·
Genomics Institute of the Novartis Research Foundation
Arthur A. Levin
·
Genomics Institute of the Novartis Research Foundation
Husam S. Younis
·
Genomics Institute of the Novartis Research Foundation
W. Michael Flanagan
·
Genomics Institute of the Novartis Research Foundation
Yiming Zhu
·
Nova Medical (United States)
Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study | Researchclopedia